Panel A: Myc positive IHC staining; Panel B: Myc negative IHC staining; Panel C: Kaplan Meier analysis (Log Rank test p = 0.01); Panel D: Univariable Cox regression.

<p>Panel A: Myc positive IHC staining; Panel B: Myc negative IHC staining; Panel C: Kaplan Meier analysis (Log Rank test p = 0.01); Panel D: Univariable Cox regression.</p

Multivariable Cox regression proportional hazards analysis of 1421 CRCs including myc IHC status and MMR/BRAF IHC phenotype interaction terms.

<p>MMRd – DNA mismatch repair deficient; MMRp – DNA mismatch repair proficient; BRAFwt – BRAF wild type; BRAFV600E – BRAFV600E mutant.</p

Multivariable Cox regression proportional hazards analysis of 1421 CRCs.

<p>Multivariable Cox regression proportional hazards analysis of 1421 CRCs.</p

Myc IHC on whole section CRCs from 2004, confirming TMA findings.

<p>Panel A: Kaplan Meier curves showing superior overall survival of CRCs with MYC over-expression compared to myc negative CRCs (Log Rank test p<0.01); Panel B: Univariable Cox regression analysis showing MYC over-expression significantly correlated with improved overall survival [hazard ratio = 0.30 (95%CI = 0.15–0.60), p<0.01].</p

Multivariable binary logistic regression showing adjusted effect of MMR/BRAF IHC phenotype on myc over-expression in 1421 CRCs.

<p>Multivariable binary logistic regression showing adjusted effect of MMR/BRAF IHC phenotype on myc over-expression in 1421 CRCs.</p

Serial H&E (A,C) and BAP1 IHC (B, D) stained sections of pancreatic ductal adenocarcinomas which demonstrate positive immunohistochemical staining for BAP1.

<p>All the neoplastic and non-neoplastic cell demonstrate diffuse strong nuclear staining (Original magnification A,B 100x, C,D 400x).</p

Kaplan-Meier survival curve for 306 pancreatic ductal adenocarcinoma patients.

<p>Kaplan-Meier survival curve for 306 pancreatic ductal adenocarcinoma patients.</p

Clinical and pathological characteristics of 306 pancreatic adenocarcinoma patients.

<p>Clinical and pathological characteristics of 306 pancreatic adenocarcinoma patients.</p

Clinical and pathological characteristics of 1421 consecutive CRC patients (2004–2009).

<p>*Reports on the significance of differences between myc positive and negative groups for each variable, using either Pearson chi-square test (with continuity correction for 2×2 tables) for categorical variables or Mann-Whitney U test for age.</p

Haematoxylin & eosin (A, C) and BAP1 immunohistochemistry (B, D) stained sections from the sole pancreatic ductal adenocarcinoma patient who expressed loss of nuclear BAP1.

<p>In this case, the exocrine cells (solid arrows) clearly lacked the brown BAP1 staining, and the non-neoplastic endothelial cells serve as the internal positive controls (hollow arrows). Magnifications: A, B 100x; C, D 400x.</p